Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.

Bradley McGregor,Daniel M Geynisman,Mauricio Burotto,Camillo Porta,Cristina Suarez,Maria T Bourlon,Viviana Del Tejo,Ella X Du,Xiaoran Yang,Selvam R Sendhil,Keith A Betts,Stephen Huo

The oncologist（2023）

引用 0|浏览14

暂无评分

摘要

Patients with aRCC treated with first-line nivolumab-based therapies had lower grade 3/4 all-cause and treatment-related AE costs than pembrolizumab-based therapies, suggesting a more favorable cost-benefit profile.

查看译文

关键词

advanced renal cell carcinoma,adverse event cost,nivolumab plus cabozantinib,nivolumab plus ipilimumab,pembrolizumab plus axitinib,pembrolizumab plus lenvatinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要